| abstract |
The present invention provides novel 16-ene-C25-oxime and 16-ene-C-25-oxime ether analogs of 1.alpha.,25-dihydroxy vitamin D3, compositions comprising these compounds and methods of using these compounds as inhibitors of CYP24. In particular, the compound of Formula I are useful for treating diseases which benefit from a modulation of the levels of 1.alpha.,25-dihydroxy vitamin D3, for example, cell-proliferative disorders. |